Research ArticleChemotherapy, Antibiotics, and Gene Therapy
The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function In Vitro and In Vivo and Augments the Activity of Fludarabine in Chronic Lymphocytic Leukemia
Stephen E. Spurgeon, Greg Coffey, Luke B. Fletcher, Russell Burke, Jeffrey W. Tyner, Brian J. Druker, Andreas Betz, Francis DeGuzman, Yvonne Pak, Dale Baker, Anjali Pandey, Stanley J. Hollenbach, Uma Sinha and Marc M. Loriaux
Journal of Pharmacology and Experimental Therapeutics February 2013, 344 (2) 378-387; DOI: https://doi.org/10.1124/jpet.112.200832
Stephen E. Spurgeon
Laboratories Oregon Health and Science University Knight Cancer Institute, Portland, Oregon (S.E.S., L.B.F., R.B., J.W.T., B.J.D., M.M.L.); Howard Hughes Medical Institute (B.J.D.), and Portola Pharmaceuticals, Inc., South San Francisco, California (G.C., A.B., F.D., Y.P., D.B., A.P., S.H., U.S.)
Greg Coffey
Laboratories Oregon Health and Science University Knight Cancer Institute, Portland, Oregon (S.E.S., L.B.F., R.B., J.W.T., B.J.D., M.M.L.); Howard Hughes Medical Institute (B.J.D.), and Portola Pharmaceuticals, Inc., South San Francisco, California (G.C., A.B., F.D., Y.P., D.B., A.P., S.H., U.S.)
Luke B. Fletcher
Laboratories Oregon Health and Science University Knight Cancer Institute, Portland, Oregon (S.E.S., L.B.F., R.B., J.W.T., B.J.D., M.M.L.); Howard Hughes Medical Institute (B.J.D.), and Portola Pharmaceuticals, Inc., South San Francisco, California (G.C., A.B., F.D., Y.P., D.B., A.P., S.H., U.S.)
Russell Burke
Laboratories Oregon Health and Science University Knight Cancer Institute, Portland, Oregon (S.E.S., L.B.F., R.B., J.W.T., B.J.D., M.M.L.); Howard Hughes Medical Institute (B.J.D.), and Portola Pharmaceuticals, Inc., South San Francisco, California (G.C., A.B., F.D., Y.P., D.B., A.P., S.H., U.S.)
Jeffrey W. Tyner
Laboratories Oregon Health and Science University Knight Cancer Institute, Portland, Oregon (S.E.S., L.B.F., R.B., J.W.T., B.J.D., M.M.L.); Howard Hughes Medical Institute (B.J.D.), and Portola Pharmaceuticals, Inc., South San Francisco, California (G.C., A.B., F.D., Y.P., D.B., A.P., S.H., U.S.)
Brian J. Druker
Laboratories Oregon Health and Science University Knight Cancer Institute, Portland, Oregon (S.E.S., L.B.F., R.B., J.W.T., B.J.D., M.M.L.); Howard Hughes Medical Institute (B.J.D.), and Portola Pharmaceuticals, Inc., South San Francisco, California (G.C., A.B., F.D., Y.P., D.B., A.P., S.H., U.S.)
Andreas Betz
Laboratories Oregon Health and Science University Knight Cancer Institute, Portland, Oregon (S.E.S., L.B.F., R.B., J.W.T., B.J.D., M.M.L.); Howard Hughes Medical Institute (B.J.D.), and Portola Pharmaceuticals, Inc., South San Francisco, California (G.C., A.B., F.D., Y.P., D.B., A.P., S.H., U.S.)
Francis DeGuzman
Laboratories Oregon Health and Science University Knight Cancer Institute, Portland, Oregon (S.E.S., L.B.F., R.B., J.W.T., B.J.D., M.M.L.); Howard Hughes Medical Institute (B.J.D.), and Portola Pharmaceuticals, Inc., South San Francisco, California (G.C., A.B., F.D., Y.P., D.B., A.P., S.H., U.S.)
Yvonne Pak
Laboratories Oregon Health and Science University Knight Cancer Institute, Portland, Oregon (S.E.S., L.B.F., R.B., J.W.T., B.J.D., M.M.L.); Howard Hughes Medical Institute (B.J.D.), and Portola Pharmaceuticals, Inc., South San Francisco, California (G.C., A.B., F.D., Y.P., D.B., A.P., S.H., U.S.)
Dale Baker
Laboratories Oregon Health and Science University Knight Cancer Institute, Portland, Oregon (S.E.S., L.B.F., R.B., J.W.T., B.J.D., M.M.L.); Howard Hughes Medical Institute (B.J.D.), and Portola Pharmaceuticals, Inc., South San Francisco, California (G.C., A.B., F.D., Y.P., D.B., A.P., S.H., U.S.)
Anjali Pandey
Laboratories Oregon Health and Science University Knight Cancer Institute, Portland, Oregon (S.E.S., L.B.F., R.B., J.W.T., B.J.D., M.M.L.); Howard Hughes Medical Institute (B.J.D.), and Portola Pharmaceuticals, Inc., South San Francisco, California (G.C., A.B., F.D., Y.P., D.B., A.P., S.H., U.S.)
Stanley J. Hollenbach
Laboratories Oregon Health and Science University Knight Cancer Institute, Portland, Oregon (S.E.S., L.B.F., R.B., J.W.T., B.J.D., M.M.L.); Howard Hughes Medical Institute (B.J.D.), and Portola Pharmaceuticals, Inc., South San Francisco, California (G.C., A.B., F.D., Y.P., D.B., A.P., S.H., U.S.)
Uma Sinha
Laboratories Oregon Health and Science University Knight Cancer Institute, Portland, Oregon (S.E.S., L.B.F., R.B., J.W.T., B.J.D., M.M.L.); Howard Hughes Medical Institute (B.J.D.), and Portola Pharmaceuticals, Inc., South San Francisco, California (G.C., A.B., F.D., Y.P., D.B., A.P., S.H., U.S.)
Marc M. Loriaux
Laboratories Oregon Health and Science University Knight Cancer Institute, Portland, Oregon (S.E.S., L.B.F., R.B., J.W.T., B.J.D., M.M.L.); Howard Hughes Medical Institute (B.J.D.), and Portola Pharmaceuticals, Inc., South San Francisco, California (G.C., A.B., F.D., Y.P., D.B., A.P., S.H., U.S.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleChemotherapy, Antibiotics, and Gene Therapy
Syk Inhibition Augments Fludarabine Activity in CLL
Stephen E. Spurgeon, Greg Coffey, Luke B. Fletcher, Russell Burke, Jeffrey W. Tyner, Brian J. Druker, Andreas Betz, Francis DeGuzman, Yvonne Pak, Dale Baker, Anjali Pandey, Stanley J. Hollenbach, Uma Sinha and Marc M. Loriaux
Journal of Pharmacology and Experimental Therapeutics February 1, 2013, 344 (2) 378-387; DOI: https://doi.org/10.1124/jpet.112.200832
Research ArticleChemotherapy, Antibiotics, and Gene Therapy
Syk Inhibition Augments Fludarabine Activity in CLL
Stephen E. Spurgeon, Greg Coffey, Luke B. Fletcher, Russell Burke, Jeffrey W. Tyner, Brian J. Druker, Andreas Betz, Francis DeGuzman, Yvonne Pak, Dale Baker, Anjali Pandey, Stanley J. Hollenbach, Uma Sinha and Marc M. Loriaux
Journal of Pharmacology and Experimental Therapeutics February 1, 2013, 344 (2) 378-387; DOI: https://doi.org/10.1124/jpet.112.200832
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement